Randomized phase II trial of sulindac for lung cancer chemoprevention

Lung Cancer

Volumn 79, Issue 3, 2013, Pages 254-261

  Limburg, Paul J ^a   Mandrekar, Sumithra J ^a   Aubry, Marie Christine ^a   Ziegler, Katie L Allen ^a   Zhang, Jun ^a   Yi, Joanne E ^a   Henry, Michael ^a   Tazelaar, Henry D ^b   Lam, Stephen ^c   McWilliams, Annette ^c   Midthun, David E ^a   Edell, Eric S ^a   Rickman, Otis B ^a   Mazzone, Peter ^d   Tockman, Melvyn ^e   Beamis, John F ^f   Lamb, Carla ^f   Simoff, Michael ^g   Loprinzi, Charles ^a   Szabo, Eva ^h   Jett, James ^a   more..

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

^d LERNER RESEARCH INSTITUTE   (United States)

^e H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^f LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^g HENRY FORD HOSPITAL   (United States)

^h NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Chemoprevention; Lung cancer; NSAIDs; Phase II clinical trial; Sulindac

Indexed keywords

KI 67 ANTIGEN; PLACEBO; SULINDAC;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BRONCHOSCOPY; BRONCHUS DISEASE; CANCER GRADING; CANCER GROWTH; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; EDEMA; FEMALE; FLUORESCENCE BRONCHOSCOPY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LEG MUSCLE WEAKNESS; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE WEAKNESS; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL TRANSFORMATION, NEOPLASTIC; CHEMOPREVENTION; FEMALE; HUMANS; INTERDISCIPLINARY STUDIES; LUNG NEOPLASMS; MALE; MIDDLE AGED; SMOKING; SULINDAC; TREATMENT OUTCOME;

EID: 84873199055     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.11.011     Document Type: Article

References (41)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Gray J., Mao J.T., Szabo E., Kelley M., Kurie J., Bepler G. Lung cancer chemoprevention: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007, 132:56S-68S.
3. Cigarette smoking among adults-United States, 2007. MMWR Morb Mortal Wkly Rep 2006, 56:1157-1161.
4. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
5. Haussinger K., Becker H., Stanzel F., Kreuzer A., Schmidt B., Strausz J., et al. Autofluorescence bronchoscopy with white light bronchoscopy compared with white light bronchoscopy alone for the detection of precancerous lesions: a European randomised controlled multicentre trial. Thorax 2005, 60:496-503.
6. Hirsch F.R., Prindiville S.A., Miller Y.E., Franklin W.A., Dempsey E.C., Murphy J.R., et al. Fluorescence versus white-light bronchoscopy for detection of preneoplastic lesions: a randomized study. J Natl Cancer Inst 2001, 93:1385-1391.
7. Lam S., Kennedy T., Unger M., Miller Y.E., Gelmont D., Rusch V., et al. Localization of bronchial intraepithelial neoplastic lesions by fluorescence bronchoscopy. Chest 1998, 113:696-702.
8. Auerbach O., Stout A.P., Hammond E.C., Garfinkel L. Changes in bronchial epithelium in relation to cigarette smoking and in relation to lung cancer. N Engl J Med 1961, 265:253-267.
9. Saccomanno G., Archer V.E., Auerbach O., Saunders R.P., Brennan L.M. Development of carcinoma of the lung as reflected in exfoliated cells. Cancer 1974, 33:256-270.
10. Szabo E. Altered histology provides a positive clinical signal in the bronchial epithelium. Cancer Prev Res 2011, 4:775-778.
11. Lam S., MacAulay C., Le Riche J.C., Dyachkova Y., Coldman A., Guillaud M., et al. A randomized phase IIb trial of anethole dithiolethione in smokers with bronchial dysplasia. J Natl Cancer Inst 2002, 94:1001-1009.
12. Lam S., Xu X., Parker-Klein H., Le Riche J.C., Macaulay C., Guillaud M., et al. Surrogate end-point biomarker analysis in a retinol chemoprevention trial in current and former smokers with bronchial dysplasia. Int J Oncol 2003, 23:1607-1613.
13. Lam S., McWilliams A., LeRiche J., MacAulay C., Wattenberg L., Szabo E. A phase I study of myo-inositol for lung cancer chemoprevention. Cancer Epidemiol Biomarkers Prev 2006, 15:1526-1531.
14. Keith R.L., Blatchford P.J., Kittelson J., Minna J.D., Kelly K., Massion P.P., et al. Oral iloprost improves endobronchial dysplasia in former smokers. Cancer Prev Res 2011, 4:793-802.
15. Cuzick J., Otto F., Baron J.A., Brown P.H., Burn J., Greenwald P., et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol 2009, 10:501-507.
16. Brown J.R., DuBois R.N. Cyclooxygenase as a target in lung cancer. Clin Cancer Res 2004, 10:4266s-4269s.
17. Lee J.M., Yanagawa J., Peebles K.A., Sharma S., Mao J.T., Dubinett S.M. Inflammation in lung carcinogenesis: new targets for lung cancer chemoprevention and treatment. Crit Rev Oncol Hematol 2008, 66:208-217.
18. Liao Z., Milas L. COX-2 and its inhibition as a molecular target in the prevention and treatment of lung cancer. Expert Rev Anticancer Ther 2004, 4:543-560.
19. Rioux N., Castonguay A. Induction of COX expression by a tobacco carcinogen: implication in lung cancer chemoprevention. Inflamm Res 1999, 48:S136-S137.
20. Duperron C., Castonguay A. Chemopreventive efficacies of aspirin and sulindac against lung tumorigenesis in A/J mice. Carcinogenesis 1997, 18:1001-1006.
21. Mao J.T., Fishbein M.C., Adams B., Roth M.D., Goodglick L., Hong L., et al. Celecoxib decreases Ki-67 proliferative index in active smokers. Clinical cancer research: an official journal of the American Association for Cancer Research 2006, 12:314-320.
22. Mao J.T., Roth M.D., Fishbein M.C., Aberle D.R., Zhang Z.F., Rao J.Y., et al. Lung cancer chemoprevention with celecoxib in former smokers. Cancer Prev Res 2011, 4:984-993.
23. Kim E.S., Hong W.K., Lee J.J., Mao L., Morice R.C., Liu D.D., et al. Biological activity of celecoxib in the bronchial epithelium of current and former smokers. Cancer Prev Res 2010, 3:148-159.
24. Mukherjee D. Selective cyclooxygenase-2 (COX-2) inhibitors and potential risk of cardiovascular events. Biochem Pharmacol 2002, 63:817-821.
25. Brophy J.M. Celecoxib and cardiovascular risks. Expert Opinon Drug Saf 2005, 4:1005-1015.
26. Reid J.M., Mandrekar S.J., Carlson E.C., Harmsen W.S., Green E.M., McGovern R.M., et al. Comparative bioavailability of sulindac in capsule and tablet formulations. Cancer Epidemiol Biomarkers Prev 2008, 17:674-679.
27. Nicholson A.G., Perry L.J., Cury P.M., Jackson P., McCormick C.M., Corrin B., et al. Reproducibility of the WHO/IASLC grading system for pre-invasive squamous lesions of the bronchus: a study of inter-observer and intra-observer variation. Histopathology 2001, 38:202-208.
28. Peto R., Gray R., Collins R., Wheatley K., Hennekens C., Jamrozik K., et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J 1988, 296:313-316.
29. Cook N.R., Lee I.M., Gaziano J.M., Gordon D., Ridker P.M., Manson J.E., et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. J Am Med Assoc 2005, 294:47-55.
30. Rothwell P.M., Fowkes F.G., Belch J.F., Ogawa H., Warlow C.P., Meade T.W. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011, 377:31-41.
31. Mao J.T., Cui X., Reckamp K., Liu M., Krysan K., Dalwadi H., et al. Chemoprevention strategies with cyclooxygenase-2 inhibitors for lung cancer. Clin Lung Cancer 2005, 7:30-39.
32. De Flora S., Izzotti A., D'Agostini F., Bennicelli C., You M., Lubet R.A., et al. Induction and modulation of lung tumors: genomic and transcriptional alterations in cigarette smoke-exposed mice. Exp Lung Res 2005, 31:19-35.
33. Hecht S.S., Kassie F., Hatsukami D.K. Chemoprevention of lung carcinogenesis in addicted smokers and ex-smokers. Nat Rev Cancer 2009, 9:476-488.
34. Edell E., Lam S., Pass H., Miller Y.E., Sutedja T., Kennedy T., et al. Detection and localization of intraepithelial neoplasia and invasive carcinoma using fluorescence-reflectance bronchoscopy: an international, multicenter clinical trial. J Thorac Oncol 2009, 4:49-54.
35. Kye S.H., Tashkin D.P., Roth M.D., Adams B., Nie W.X., Mao J.T. Recruitment strategies for a lung cancer chemoprevention trial involving ex-smokers. Contemp Clin Trials 2009, 30:464-472.
36. Dragnev K.H., Stover D., Dmitrovsky E. Lung cancer prevention: the guidelines. Chest 2003, 123:60S-71S.
37. Counseling and interventions to prevent tobacco use and tobacco-caused disease in adults and pregnant women: U.S. Preventive Services Task Force reaffirmation recommendation statement. Ann Intern Med 2009, 150:551-555.
38. Cheong Y., Yong H.H., Borland R. Does how you quit affect success? A comparison between abrupt and gradual methods using data from the International Tobacco Control Policy Evaluation Study. Nicotine Tob Res 2007, 9:801-810.
39. Fagan P., Augustson E., Backinger C.L., O'Connell M.E., Vollinger R.E., Kaufman A., et al. Quit attempts and intention to quit cigarette smoking among young adults in the United States. Am J Public Health 2007, 97:1412-1420.
40. Shiffman S., Brockwell S.E., Pillitteri J.L., Gitchell J.G. Use of smoking-cessation treatments in the United States. Am J Prev Med 2008, 34:102-111.
41. Aberle D.R., Adams A.M., Berg C.D., Black W.C., Clapp J.D., Fagerstrom R.M., et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011, 365:395-409.